Online inquiry

IVTScrip™ mRNA-Human AKT3, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK21382MR)

This product GTTS-WK21382MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the AKT3 protein. This product can be used in Oogenesis phase fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001206729.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 10000
UniProt ID Q9Y243
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human AKT3, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK21382MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WK8324MR IVTScrip™ mRNA-Human ADCY9, (Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADCY9
GTTS-WK26725MR IVTScrip™ mRNA-Human APOBEC4, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA APOBEC4
GTTS-WK10713MR IVTScrip™ mRNA-Human ADARB1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADARB1
GTTS-WK17805MR IVTScrip™ mRNA-Human ALDH7A1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALDH7A1
GTTS-WK12424MR IVTScrip™ mRNA-Human Acetylcholinesterase, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Acetylcholinesterase
GTTS-WK15131MR IVTScrip™ mRNA-Human ALOX15B, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALOX15B
GTTS-WK18636MR IVTScrip™ mRNA-Human AIMP2, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AIMP2
GTTS-WK18401MR IVTScrip™ mRNA-Human ALDH3B1, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALDH3B1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW